Journal
JOURNAL OF CONTROLLED RELEASE
Volume 164, Issue 1, Pages 8-16Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2012.10.001
Keywords
Heparin-taurocholate; LMWH; cRGD; alpha(v)beta(3) integrin; Angiogenesis inhibitor
Funding
- World Class University (WCU) program [R31-2008-000-10103]
- Converging Research Center Program [2011K000809]
- National Research Foundation of Korea (NRF) [2010-0027955]
- Korean Ministry of Education, Science and Technology
Ask authors/readers for more resources
LMWH-taurocholate derivative (LHT7) has been reported as a novel angiogenesis inhibitor, due to its ability to bind to several kinds of growth factors, which play critical roles in tumor angiogenesis. In this study, we have highlighted the enhanced antiangiogenic activity of LHT7, by using cyclic RGDyk (cRGD), a targeting moiety that was chemically conjugated to LHT7 via amide bond. The SPR study revealed that cRGD-LHT7 bound to alpha(v)beta(3) integrin as strongly as cRGD, and it bound to VEGF as strongly as LHT7. Importantly, in vitro anti-angiogenesis studies revealed that cRGD-LHT7 had a significant inhibition effect on HUVEC tubular formation. Finally, cRGD-LHT7 showed a greater inhibitory efficiency on the tumor growth in the U87MG xenograft model than the original LHT7, which was owed to its ability to target the tumor cells. All of these findings demonstrated that cRGD-LHT7 targeted alpha(v)beta(3) integrin-positive cancer cells and endothelial cells, resulting in a greater anti-angiogenesis effect on the solid tumors. (C) 2012 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available